Moreover, CD8+ T cells showed an increasing trend within the tumor microenvironment (Figure 4E) in all the groups that underwent adenovirus-based treatment (Ad5/3Δ24, AdTRP2, and PeptiCRAd); however, a tendency in increased effector phenotype CXCR3+ among the CD8+ T cells was reported only in PeptiCRAd treated group (Figure 4F). This evidence concerns the gene CXCR3 and neoplasm.